Details of the Drug Combination

General Information of Drug Combination (ID: DCRLOPH)

Drug Combination Name
CA4P RTB101
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs CA4P   DM9R0ZL RTB101   DM62QTW
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: SU-DIPG-XIII
Zero Interaction Potency (ZIP) Score: 8.177
Bliss Independence Score: 7.201
Loewe Additivity Score: 13.29
LHighest Single Agent (HSA) Score: 14.55

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CA4P
Disease Entry ICD 11 Status REF
Neuroendocrine cancer 2B72.1 Phase 2 [2]
Ovarian cancer 2C73 Phase 2 [2]
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
5 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.